Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 29, 2024 (filed on Feb 29, 2024)Insider Name:Lee Willis COwnership Type:Indirect OwnershipSecurities:Common stock, $0.001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:77,000Price:$0.13
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Lee Willis COwnership Type:Indirect OwnershipSecurities:Common stock, $0.001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:15,000Price:$0.12
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Lee Willis COwnership Type:Indirect OwnershipSecurities:Common stock, $0.001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:10,000Price:$0.13
-
Feb 26, 2024 (filed on Feb 29, 2024)Insider Name:Lee Willis COwnership Type:Indirect OwnershipSecurities:Common stock, $0.001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:13,200Price:$0.12
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Zwicker Ian HarveyOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:$0.15
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:ZEN Wei PeuOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:$0.15
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Lim Seah H.Ownership Type:Direct OwnershipSecurities:OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:$0.15
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Stark Charles WilliamOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:$0.15
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Sekulich GeorgeOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:$0.15
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Nagasaki YasushiOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:$0.15
Filings by filing date
-
Feb 29, 2024 (filed on Feb 29, 2024)Insider Name:Lee Willis COwnership Type:Indirect OwnershipSecurities:Common stock, $0.001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:77,000Price:$0.13
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Lee Willis COwnership Type:Indirect OwnershipSecurities:Common stock, $0.001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:15,000Price:$0.12
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Lee Willis COwnership Type:Indirect OwnershipSecurities:Common stock, $0.001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:10,000Price:$0.13
-
Feb 26, 2024 (filed on Feb 29, 2024)Insider Name:Lee Willis COwnership Type:Indirect OwnershipSecurities:Common stock, $0.001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:13,200Price:$0.12
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Zwicker Ian HarveyOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:$0.15
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:ZEN Wei PeuOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:$0.15
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Lim Seah H.Ownership Type:Direct OwnershipSecurities:OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:$0.15
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Stark Charles WilliamOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:$0.15
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Sekulich GeorgeOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:$0.15
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Nagasaki YasushiOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:$0.15
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 |
Tel: | N/A |
Website: | https://www.emmausmedical.com |
IR: | See website |
Key People | ||
Willis C. Lee Chairman of the Board, Co-President, Chief Operating Officer, Executive Director | George Sekulich Co-President, Senior Vice President - Global Commercialization, Chief Information Officer, Director | Yasushi Nagasaki Chief Financial Officer | Charles Stark Senior Vice President - Medical Affairs, Clinical, Regulatory |
Business Overview |
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing, and sale of treatments and therapies, primarily for rare and orphan diseases. The Company's lead product, Endari (prescription-grade L-glutamine oral powder), helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients aged five years and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainos's IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. It has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells. |
Financial Overview |
For the nine months ended 30 September 2023, Emmaus Life Sciences Inc revenues increased 81% to $22.5M. Net loss decreased 54% to $4.9M. Revenues reflect Endari segment increase of 82% to $21.9M, Other segment increase of 56% to $605K. Lower net loss reflects Foreign exchange loss decrease of 37% to $3.2M (expense), Research and development decrease of 14% to $1M (expense). |
Employees: | 55 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $35.87M as of Sep 30, 2023 |
Annual revenue (TTM): | $28.46M as of Sep 30, 2023 |
EBITDA (TTM): | $0.81M as of Sep 30, 2023 |
Net annual income (TTM): | -$4.74M as of Sep 30, 2023 |
Free cash flow (TTM): | -$0.88M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | $30.93M as of Sep 30, 2023 |
Shares outstanding: | 53,637,554 as of Nov 10, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |